Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G] and IgA Nephropathy [IgAN]). In Part 1 of the study, HVs will receive a single dose of ARO-C3 or placebo. In Part 2 of the study, adult patients with PNH or C3G/IgAN will receive 2 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Arrowhead Pharmaceuticals

Criteria

Inclusion Criteria (All Participants):

• Willing to provide written informed consent and to comply with study requirements

• Female participants must be non-pregnant/non-lactating

• Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. PNH, C3G and IgAN participants must have been vaccinated or willing to undergo vaccination

• All participants must be willing to be vaccinated or have a history of vaccination for Haemophilus influenzae

• Body Mass Index (BMI) between 18.0 and 35.0 kg/m2

• 12-lead electrocardiogram (ECG) at Screening with no abnormalities that may compromise participant's safety at discretion of investigator

• Participants of childbearing potential must use highly effective contraception during the study and for at least 12 weeks following the end of the study or last dose of study drug, whichever is later. Males must not donate sperm during the study and for at least 12 weeks following the end of the study or last dose of study drug, whichever is later.

• No abnormal finding of clinical relevance at the Screening evaluation that, in the opinion of the investigator, could adversely impact participant safety or study results

Inclusion Criteria (PNH Participants):

• Diagnosis of PNH

Inclusion Criteria (C3G and IgAN Participants):

• Diagnosis of C3G or IgAN

• Clinical evidence of ongoing disease based on significant proteinuria

• Estimated glomerular filtration rate ≥40 mL/Min/1.73 m2 at Screening and currently not on dialysis

• Must be on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)

Exclusion Criteria (All Participants):

• Seropositive for human immunodeficiency virus (HIV) infection,hepatitis B virus, or hepatitis C virus

• History of recurrent or chronic infections

• Uncontrolled hypertension

• Regular usee of alcohol within 30 days prior to Screening

• Use of illicit drugs within 1 year prior to Screening or positive urine drug screen at Screening

• History of meningococcal infection

• History of asplenia or splenectomy

• Known contraindication or history of anaphylactic reaction to any vaccine or vaccine component or prophylactic antibiotics planned for use in the study

• Any medical or surgical condition that, in the opinion of the investigator, would expose the participant to a significant safety risk or compromise the results of the study

Note: Additional Inclusion/Exclusion criteria may apply per protocol